{
  "DOI": "10.1186/s40246-023-00493-5",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-023-00493-5",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eHER2-positive breast cancer occurs in 15–20% of breast cancer patients and is characterized by poor prognosis. Trastuzumab is considered the key drug for treatment of HER2-positive breast cancer patients. It improves patient survival; however, resistance to trastuzumab remains a challenge in HER2-positive breast cancer patients. Therefore, the prediction of response to trastuzumab is crucial to choose optimal treatment regimens. The aim of the study was to identify genetic variants that could predict response to anti-HER2-targeted therapy (trastuzumab) using next-generation sequencing.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eMethod\u003c/jats:title\u003e\n                \u003cjats:p\u003eGenetic variants in the hotspot regions of 17 genes were studied in 24 Formalin-Fixed Paraffin-Embedded (FFPE) samples using Ion S5 next-generation sequencing system. FFPE samples were collected from HER2‑positive breast cancer patients previously treated with anti‑HER2‑targeted treatment (Trastuzumab). Patients were divided into two groups; trastuzumab-sensitive group and trastuzumab-resistant group based on their response to targeted therapy.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eWe identified 29 genetic variants in nine genes that only occurred in trastuzumab-resistant patients and could be associated with resistance to targeted therapy including \u003cjats:italic\u003eTP53, ATM, RB1, MLH1, SMARCB1, SMO\u003c/jats:italic\u003e, \u003cjats:italic\u003eGNAS\u003c/jats:italic\u003e, \u003cjats:italic\u003eCDH1\u003c/jats:italic\u003e, and \u003cjats:italic\u003eVHL.\u003c/jats:italic\u003e Four variants out of these 29 variants were repeated in more than one patient; two variants in \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e, one variant in \u003cjats:italic\u003eATM\u003c/jats:italic\u003e gene, and the last variant in \u003cjats:italic\u003eRB1\u003c/jats:italic\u003e gene. In addition, three genes were found to be mutated only in resistant patients; \u003cjats:italic\u003eMLH1, SMARCB1 and SMO\u003c/jats:italic\u003e genes. Moreover, one novel allele (c.407A \u0026gt; G, p. Gln136Arg) was detected within exon 4 of \u003cjats:italic\u003eTP53\u003c/jats:italic\u003e gene in one resistant patient.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusion\u003c/jats:title\u003e\n                \u003cjats:p\u003eNGS sequencing is a useful tool to detect genetic variants that could predict response to trastuzumab therapy.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "493"
  ],
  "article-number": "43",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "9 January 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "9 May 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "18 May 2023"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The study was approved by the Ethics Committee of Alexandria University, Egypt. Informed consent was obtained from all individual participants included in the study. All methods were performed in accordance with the relevant guidelines and regulations."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Not applicable."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "The authors declare that they have no conflicts of interest that are directly relevant to the content of this article."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Zakaria",
      "given": "Nermine H.",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Hashad",
      "given": "Doaa",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Saied",
      "given": "Marwa H.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Hegazy",
      "given": "Neamat",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Elkayal",
      "given": "Alyaa",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-3742-6438",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Tayae",
      "given": "Eman",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ],
    "date-time": "2023-05-18T08:03:15Z",
    "timestamp": 1684396995000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ],
    "date-time": "2023-05-18T09:08:32Z",
    "timestamp": 1684400912000
  },
  "funder": [
    {
      "name": "The Science, Technology \u0026 Innovation Funding Authority"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        30
      ]
    ],
    "date-time": "2024-04-30T07:50:35Z",
    "timestamp": 1714463435453
  },
  "is-referenced-by-count": 1,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2023,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            5,
            18
          ]
        ],
        "date-time": "2023-05-18T00:00:00Z",
        "timestamp": 1684368000000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            5,
            18
          ]
        ],
        "date-time": "2023-05-18T00:00:00Z",
        "timestamp": 1684368000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00493-5.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-023-00493-5/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00493-5.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.3322/caac.21660",
      "author": "H Sung",
      "doi-asserted-by": "publisher",
      "first-page": "209",
      "issue": "3",
      "journal-title": "CA Cancer J Clin",
      "key": "493_CR1",
      "unstructured": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.",
      "volume": "71",
      "year": "2021"
    },
    {
      "DOI": "10.14366/usg.16030",
      "author": "N Cho",
      "doi-asserted-by": "publisher",
      "first-page": "281",
      "issue": "4",
      "journal-title": "Ultrasonography",
      "key": "493_CR2",
      "unstructured": "Cho N. Molecular subtypes and imaging phenotypes of breast cancer. Ultrasonography. 2016;35(4):281.",
      "volume": "35",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.gendis.2018.05.001",
      "author": "Y Feng",
      "doi-asserted-by": "publisher",
      "first-page": "77",
      "issue": "2",
      "journal-title": "Genes Dis",
      "key": "493_CR3",
      "unstructured": "Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106.",
      "volume": "5",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S1470-2045(17)30021-9",
      "author": "A Llombart-Cussac",
      "doi-asserted-by": "publisher",
      "first-page": "545",
      "issue": "4",
      "journal-title": "Lancet Oncol",
      "key": "493_CR4",
      "unstructured": "Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017;18(4):545–54.",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.breast.2022.01.006",
      "author": "N Harbeck",
      "doi-asserted-by": "publisher",
      "first-page": "S12",
      "issue": "Suppl 1",
      "journal-title": "Breast",
      "key": "493_CR5",
      "unstructured": "Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast. 2022;62(Suppl 1):S12–6.",
      "volume": "62",
      "year": "2022"
    },
    {
      "DOI": "10.1200/JCO.2002.20.3.719",
      "author": "CL Vogel",
      "doi-asserted-by": "publisher",
      "first-page": "719",
      "issue": "3",
      "journal-title": "J Clin Oncol",
      "key": "493_CR6",
      "unstructured": "Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.",
      "volume": "20",
      "year": "2002"
    },
    {
      "DOI": "10.1177/1758835919833519",
      "author": "S Pernas",
      "doi-asserted-by": "crossref",
      "first-page": "175883591983351",
      "journal-title": "Ther Adv Med",
      "key": "493_CR7",
      "unstructured": "Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med. 2019;11:1758835919833519.",
      "volume": "11",
      "year": "2019"
    },
    {
      "DOI": "10.3390/ijerph17218089",
      "author": "A Mbemi",
      "doi-asserted-by": "publisher",
      "first-page": "8089",
      "issue": "21",
      "journal-title": "Int J Environ Res Public Health",
      "key": "493_CR8",
      "unstructured": "Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of gene-environment interactions on cancer development. Int J Environ Res Public Health. 2020;17(21):8089.",
      "volume": "17",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41467-021-27093-y",
      "author": "AE Smith",
      "doi-asserted-by": "publisher",
      "first-page": "6667",
      "issue": "1",
      "journal-title": "Nat Commun",
      "key": "493_CR9",
      "unstructured": "Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S. HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun. 2021;12(1):6667.",
      "volume": "12",
      "year": "2021"
    },
    {
      "DOI": "10.2353/ajpath.2010.090885",
      "author": "FJ Esteva",
      "doi-asserted-by": "publisher",
      "first-page": "1647",
      "issue": "4",
      "journal-title": "Am J Pathol",
      "key": "493_CR10",
      "unstructured": "Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177(4):1647–56.",
      "volume": "177",
      "year": "2010"
    },
    {
      "DOI": "10.1101/cshperspect.a036269",
      "author": "ER Mardis",
      "doi-asserted-by": "publisher",
      "issue": "9",
      "journal-title": "Cold Spring Harb Perspect Med",
      "key": "493_CR11",
      "unstructured": "Mardis ER. The impact of next-generation sequencing on cancer genomics: from discovery to clinic. Cold Spring Harb Perspect Med. 2019;9(9): a036269.",
      "volume": "9",
      "year": "2019"
    },
    {
      "DOI": "10.1093/jnci/djt121",
      "author": "S Loi",
      "doi-asserted-by": "publisher",
      "first-page": "960",
      "issue": "13",
      "journal-title": "J Natl Cancer Inst",
      "key": "493_CR12",
      "unstructured": "Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen P-L, et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst. 2013;105(13):960–7.",
      "volume": "105",
      "year": "2013"
    },
    {
      "DOI": "10.1007/s10549-011-1412-7",
      "author": "S Glück",
      "doi-asserted-by": "publisher",
      "first-page": "781",
      "issue": "3",
      "journal-title": "Breast Cancer Res Treat",
      "key": "493_CR13",
      "unstructured": "Glück S, Ross JS, Royce M, McKenna EF, Perou CM, Avisar E, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine±trastuzumab. Breast Cancer Res Treat. 2012;132(3):781–91.",
      "volume": "132",
      "year": "2012"
    },
    {
      "DOI": "10.1038/ncomms7886",
      "author": "V Stagni",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Nat Commun",
      "key": "493_CR14",
      "unstructured": "Stagni V, Manni I, Oropallo V, Mottolese M, Di Benedetto A, Piaggio G, et al. ATM kinase sustains HER2 tumorigenicity in breast cancer. Nat Commun. 2015;6(1):1–10.",
      "volume": "6",
      "year": "2015"
    },
    {
      "DOI": "10.1177/1758835919891608",
      "author": "E Risi",
      "doi-asserted-by": "publisher",
      "first-page": "175883591989160",
      "journal-title": "Ther Adv Med Oncol",
      "key": "493_CR15",
      "unstructured": "Risi E, Biagioni C, Benelli M, Migliaccio I, McCartney A, Bonechi M, et al. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Ther Adv Med Oncol. 2019;11:1758835919891608.",
      "volume": "11",
      "year": "2019"
    },
    {
      "DOI": "10.31276/VJSTE.60(2).30",
      "author": "HT Nguyen",
      "doi-asserted-by": "publisher",
      "first-page": "30",
      "issue": "2",
      "journal-title": "VJSTE",
      "key": "493_CR16",
      "unstructured": "Nguyen HT, Le HT, Nguyen LT, Lou H, LaFramboise T. The applications of massive parallel sequencing (next-generation sequencing) in research and molecular diagnosis of human genetic diseases. VJSTE. 2018;60(2):30–43.",
      "volume": "60",
      "year": "2018"
    },
    {
      "DOI": "10.1371/journal.pone.0064271",
      "author": "S-W Han",
      "doi-asserted-by": "publisher",
      "issue": "5",
      "journal-title": "PLoS ONE",
      "key": "493_CR17",
      "unstructured": "Han S-W, Kim H-P, Shin J-Y, Jeong E-G, Lee W-C, Lee K-H, et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS ONE. 2013;8(5): e64271.",
      "volume": "8",
      "year": "2013"
    },
    {
      "DOI": "10.1038/s41588-020-0609-2",
      "author": "H Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "572",
      "issue": "6",
      "journal-title": "Nat Genet",
      "key": "493_CR18",
      "unstructured": "Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020;52(6):572–81.",
      "volume": "52",
      "year": "2020"
    },
    {
      "DOI": "10.1038/jid.2013.248",
      "author": "A Grada",
      "doi-asserted-by": "publisher",
      "issue": "8",
      "journal-title": "J Investig Dermatol",
      "key": "493_CR19",
      "unstructured": "Grada A, Weinbrecht K. Next-generation sequencing: methodology and application. J Investig Dermatol. 2013;133(8): e11.",
      "volume": "133",
      "year": "2013"
    },
    {
      "DOI": "10.1073/pnas.1431692100",
      "author": "S Kato",
      "doi-asserted-by": "publisher",
      "first-page": "8424",
      "issue": "14",
      "journal-title": "Proc Nat Acad Sci U S A",
      "key": "493_CR20",
      "unstructured": "Kato S, Han S-Y, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Nat Acad Sci U S A. 2003;100(14):8424–9.",
      "volume": "100",
      "year": "2003"
    },
    {
      "DOI": "10.1186/s12885-019-5756-4",
      "author": "GN Tsaousis",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "BMC Cancer",
      "key": "493_CR21",
      "unstructured": "Tsaousis GN, Papadopoulou E, Apessos A, Agiannitopoulos K, Pepe G, Kampouri S, et al. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. BMC Cancer. 2019;19(1):1–19.",
      "volume": "19",
      "year": "2019"
    },
    {
      "DOI": "10.1038/ng1837",
      "author": "A Renwick",
      "doi-asserted-by": "publisher",
      "first-page": "873",
      "issue": "8",
      "journal-title": "Nat Genet",
      "key": "493_CR22",
      "unstructured": "Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873–5.",
      "volume": "38",
      "year": "2006"
    },
    {
      "DOI": "10.1007/s10038-005-0348-3",
      "author": "K Sampieri",
      "doi-asserted-by": "publisher",
      "first-page": "209",
      "issue": "3",
      "journal-title": "J Hum Genet",
      "key": "493_CR23",
      "unstructured": "Sampieri K, Hadjistilianou T, Mari F, Speciale C, Mencarelli MA, Cetta F, et al. Mutational screening of the RB1 gene in Italian patients with retinoblastoma reveals 11 novel mutations. J Hum Genet. 2006;51(3):209–16.",
      "volume": "51",
      "year": "2006"
    },
    {
      "DOI": "10.18632/oncotarget.3511",
      "author": "C-H Chiu",
      "doi-asserted-by": "publisher",
      "first-page": "8407",
      "issue": "10",
      "journal-title": "Oncotarget",
      "key": "493_CR24",
      "unstructured": "Chiu C-H, Ho H-L, Doong H, Yeh Y-C, Chen M-Y, Chou T-Y, et al. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. Oncotarget. 2015;6(10):8407.",
      "volume": "6",
      "year": "2015"
    },
    {
      "DOI": "10.1086/302639",
      "author": "N Sévenet",
      "doi-asserted-by": "publisher",
      "first-page": "1342",
      "issue": "5",
      "journal-title": "Am J Hum Genet",
      "key": "493_CR25",
      "unstructured": "Sévenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet. 1999;65(5):1342–8.",
      "volume": "65",
      "year": "1999"
    },
    {
      "DOI": "10.1038/34201",
      "author": "J Xie",
      "doi-asserted-by": "publisher",
      "first-page": "90",
      "issue": "6662",
      "journal-title": "Nature",
      "key": "493_CR26",
      "unstructured": "Xie J, Murone M, Luoh S-M, Ryan A, Gu Q, Zhang C, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–2.",
      "volume": "391",
      "year": "1998"
    },
    {
      "author": "X Wu",
      "first-page": "3952",
      "journal-title": "Front Pharmacol",
      "key": "493_CR27",
      "unstructured": "Wu X, Yang H, Yu X, Qin J-J. Drug-resistant HER2-positive breast cancer: molecular mechanisms and overcoming strategies. Front Pharmacol. 2022;13:3952.",
      "volume": "13",
      "year": "2022"
    },
    {
      "DOI": "10.3389/fonc.2022.1006429",
      "author": "Z-H Wang",
      "doi-asserted-by": "publisher",
      "first-page": "1006429",
      "journal-title": "Front Oncol",
      "key": "493_CR28",
      "unstructured": "Wang Z-H, Zheng Z-Q, Liu S-N, Xiao X-F, Chen G-Y, Liang W-Q, et al. Trastuzumab resistance in HER2-positive breast cancer: mechanisms, emerging biomarkers and targeting agents. Front Oncol. 2022;12:1006429.",
      "volume": "12",
      "year": "2022"
    },
    {
      "DOI": "10.1093/annonc/mdw434",
      "author": "W Shi",
      "doi-asserted-by": "publisher",
      "first-page": "128",
      "issue": "1",
      "journal-title": "Ann Oncol",
      "key": "493_CR29",
      "unstructured": "Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, et al. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Ann Oncol. 2017;28(1):128–35.",
      "volume": "28",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ygeno.2015.11.003",
      "author": "JM Heather",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Genomics",
      "key": "493_CR30",
      "unstructured": "Heather JM, Chain B. The sequence of sequencers: the history of sequencing DNA. Genomics. 2016;107(1):1–8.",
      "volume": "107",
      "year": "2016"
    },
    {
      "DOI": "10.1172/JCI68339",
      "author": "DN Hayes",
      "doi-asserted-by": "publisher",
      "first-page": "462",
      "issue": "2",
      "journal-title": "J Clin Investig",
      "key": "493_CR31",
      "unstructured": "Hayes DN, Kim WY. The next steps in next-gen sequencing of cancer genomes. J Clin Investig. 2015;125(2):462–8.",
      "volume": "125",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41392-019-0069-2",
      "author": "J Wang",
      "doi-asserted-by": "publisher",
      "first-page": "34",
      "issue": "1",
      "journal-title": "Signal Transduct Targeted Ther",
      "key": "493_CR32",
      "unstructured": "Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Targeted Ther. 2019;4(1):34.",
      "volume": "4",
      "year": "2019"
    },
    {
      "DOI": "10.4103/0366-6999.200542",
      "author": "Q Ye",
      "doi-asserted-by": "publisher",
      "first-page": "522",
      "issue": "05",
      "journal-title": "Chin Med J",
      "key": "493_CR33",
      "unstructured": "Ye Q, Qi F, Bian L, Zhang S-H, Wang T, Jiang Z-F. Circulating-free DNA mutation associated with response of targeted therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer. Chin Med J. 2017;130(05):522–9.",
      "volume": "130",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.trecan.2020.01.007",
      "author": "A Shahbandi",
      "doi-asserted-by": "publisher",
      "first-page": "98",
      "issue": "2",
      "journal-title": "Trends Cancer",
      "key": "493_CR34",
      "unstructured": "Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer. 2020;6(2):98–110.",
      "volume": "6",
      "year": "2020"
    },
    {
      "DOI": "10.1002/humu.10174",
      "author": "AL Børresen-Dale",
      "doi-asserted-by": "publisher",
      "first-page": "292",
      "issue": "3",
      "journal-title": "Hum Mutat",
      "key": "493_CR35",
      "unstructured": "Børresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003;21(3):292–300.",
      "volume": "21",
      "year": "2003"
    },
    {
      "DOI": "10.1097/CCO.0b013e328333bf00",
      "author": "EI Palmero",
      "doi-asserted-by": "publisher",
      "first-page": "64",
      "issue": "1",
      "journal-title": "Curr Opin Oncol",
      "key": "493_CR36",
      "unstructured": "Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol. 2010;22(1):64–9.",
      "volume": "22",
      "year": "2010"
    },
    {
      "DOI": "10.1111/j.1524-4741.2011.01088.x",
      "author": "R Janavičius",
      "doi-asserted-by": "publisher",
      "first-page": "409",
      "issue": "4",
      "journal-title": "Breast J",
      "key": "493_CR37",
      "unstructured": "Janavičius R, Andrėkutė K, Mickys U, Rudaitis V, Brasiūnienė B, Griškevičius L. Apparently, “BRCA-related” breast and ovarian cancer patient with germline TP53 mutation. Breast J. 2011;17(4):409–15.",
      "volume": "17",
      "year": "2011"
    },
    {
      "DOI": "10.1038/nature17676",
      "author": "S Nik-Zainal",
      "doi-asserted-by": "publisher",
      "first-page": "47",
      "issue": "7605",
      "journal-title": "Nature",
      "key": "493_CR38",
      "unstructured": "Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47–54.",
      "volume": "534",
      "year": "2016"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-13-2943",
      "author": "L Silwal-Pandit",
      "doi-asserted-by": "publisher",
      "first-page": "3569",
      "issue": "13",
      "journal-title": "Clin Cancer Res",
      "key": "493_CR39",
      "unstructured": "Silwal-Pandit L, Vollan HKM, Chin S-F, Rueda OM, McKinney S, Osako T, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevanceTP53 in breast cancer. Clin Cancer Res. 2014;20(13):3569–80.",
      "volume": "20",
      "year": "2014"
    },
    {
      "DOI": "10.1038/s41420-020-00337-4",
      "author": "O Fedorova",
      "doi-asserted-by": "publisher",
      "first-page": "100",
      "issue": "1",
      "journal-title": "Cell Death Discov",
      "key": "493_CR40",
      "unstructured": "Fedorova O, Daks A, Shuvalov O, Kizenko A, Petukhov A, Gnennaya Y, et al. Attenuation of p53 mutant as an approach for treatment Her2-positive cancer. Cell Death Discov. 2020;6(1):100.",
      "volume": "6",
      "year": "2020"
    },
    {
      "DOI": "10.1016/S1357-4310(00)01767-6",
      "author": "EH Chang",
      "doi-asserted-by": "publisher",
      "first-page": "358",
      "issue": "9",
      "journal-title": "Mol Med Today",
      "key": "493_CR41",
      "unstructured": "Chang EH, Pirollo KF, Bouker KB. Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today. 2000;6(9):358–65.",
      "volume": "6",
      "year": "2000"
    },
    {
      "DOI": "10.18632/oncotarget.9022",
      "author": "G Fountzilas",
      "doi-asserted-by": "publisher",
      "first-page": "32731",
      "issue": "22",
      "journal-title": "Oncotarget",
      "key": "493_CR42",
      "unstructured": "Fountzilas G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, et al. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget. 2016;7(22):32731.",
      "volume": "7",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nbt.3391",
      "author": "MT Chang",
      "doi-asserted-by": "publisher",
      "first-page": "155",
      "issue": "2",
      "journal-title": "Nat Biotechnol",
      "key": "493_CR43",
      "unstructured": "Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34(2):155–63.",
      "volume": "34",
      "year": "2016"
    },
    {
      "DOI": "10.1002/cam4.1376",
      "author": "J Hauke",
      "doi-asserted-by": "publisher",
      "first-page": "1349",
      "issue": "4",
      "journal-title": "Cancer Med",
      "key": "493_CR44",
      "unstructured": "Hauke J, Horvath J, Groß E, Gehrig A, Honisch E, Hackmann K, et al. Gene panel testing of 5589 BRCA 1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med. 2018;7(4):1349–58.",
      "volume": "7",
      "year": "2018"
    },
    {
      "DOI": "10.1038/gim.2017.37",
      "author": "K Nykamp",
      "doi-asserted-by": "publisher",
      "first-page": "1105",
      "issue": "10",
      "journal-title": "Genet Med",
      "key": "493_CR45",
      "unstructured": "Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho Y-Y, et al. Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria. Genet Med. 2017;19(10):1105–17.",
      "volume": "19",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41588-018-0204-y",
      "author": "AO Giacomelli",
      "doi-asserted-by": "publisher",
      "first-page": "1381",
      "issue": "10",
      "journal-title": "Nat Genet",
      "key": "493_CR46",
      "unstructured": "Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381–7.",
      "volume": "50",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.molcel.2018.06.012",
      "author": "E Kotler",
      "doi-asserted-by": "publisher",
      "first-page": "178",
      "issue": "1",
      "journal-title": "Mol Cell",
      "key": "493_CR47",
      "unstructured": "Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, et al. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell. 2018;71(1):178-90.e8.",
      "volume": "71",
      "year": "2018"
    },
    {
      "DOI": "10.1002/humu.21034",
      "author": "G Barone",
      "doi-asserted-by": "publisher",
      "first-page": "1222",
      "issue": "8",
      "journal-title": "Hum Mutat",
      "key": "493_CR48",
      "unstructured": "Barone G, Groom A, Reiman A, Srinivasan V, Byrd PJ, Taylor AMR. Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mutat. 2009;30(8):1222–30.",
      "volume": "30",
      "year": "2009"
    },
    {
      "DOI": "10.1186/bcr2919",
      "author": "DE Goldgar",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "4",
      "journal-title": "Breast Cancer Res",
      "key": "493_CR49",
      "unstructured": "Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, et al. Rare variants in the ATMgene and risk of breast cancer. Breast Cancer Res. 2011;13(4):1–9.",
      "volume": "13",
      "year": "2011"
    },
    {
      "DOI": "10.1002/humu.20323",
      "author": "DL Stredrick",
      "doi-asserted-by": "publisher",
      "first-page": "538",
      "issue": "6",
      "journal-title": "Hum Mutat",
      "key": "493_CR50",
      "unstructured": "Stredrick DL, Garcia-Closas M, Pineda MA, Bhatti P, Alexander BH, Doody MM, et al. The ATM missense mutation p. Ser49Cys (c. 146C\u003e G) and the risk of breast cancer. Hum Mutat. 2006;27(6):538–44.",
      "volume": "27",
      "year": "2006"
    },
    {
      "DOI": "10.1371/journal.pone.0116615",
      "author": "H Ayari-Jeridi",
      "doi-asserted-by": "publisher",
      "issue": "1",
      "journal-title": "PLoS ONE",
      "key": "493_CR51",
      "unstructured": "Ayari-Jeridi H, Moran K, Chebbi A, Bouguila H, Abbes I, Charradi K, et al. Mutation spectrum of RB1 gene in unilateral retinoblastoma cases from Tunisia and correlations with clinical features. PLoS ONE. 2015;10(1): e0116615.",
      "volume": "10",
      "year": "2015"
    },
    {
      "DOI": "10.1136/jmedgenet-2014-102264",
      "author": "CJ Dommering",
      "doi-asserted-by": "publisher",
      "first-page": "366",
      "issue": "6",
      "journal-title": "J Med Genet",
      "key": "493_CR52",
      "unstructured": "Dommering CJ, Mol BM, Moll AC, Burton M, Cloos J, Dorsman JC, et al. RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients. J Med Genet. 2014;51(6):366–74.",
      "volume": "51",
      "year": "2014"
    },
    {
      "DOI": "10.1101/gad.282145.116",
      "author": "NJ Dyson",
      "doi-asserted-by": "publisher",
      "first-page": "1492",
      "issue": "13",
      "journal-title": "Genes Dev",
      "key": "493_CR53",
      "unstructured": "Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 2016;30(13):1492–502.",
      "volume": "30",
      "year": "2016"
    },
    {
      "DOI": "10.1002/1098-2744(200011)29:3\u003c151::AID-MC4\u003e3.0.CO;2-6",
      "author": "I Bièche",
      "doi-asserted-by": "publisher",
      "first-page": "151",
      "issue": "3",
      "journal-title": "Mol Carcinog: Published in cooperation with the University of Texas MD Anderson Cancer Center",
      "key": "493_CR54",
      "unstructured": "Bièche I, Lidereau R. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinog: Published in cooperation with the University of Texas MD Anderson Cancer Center. 2000;29(3):151–8.",
      "volume": "29",
      "year": "2000"
    },
    {
      "DOI": "10.1038/nature11412",
      "author": "Cancer Genome Atlas N",
      "doi-asserted-by": "publisher",
      "first-page": "61",
      "issue": "7418",
      "journal-title": "Nature",
      "key": "493_CR55",
      "unstructured": "Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.",
      "volume": "490",
      "year": "2012"
    },
    {
      "DOI": "10.1038/s41598-018-37186-2",
      "author": "SE Lee",
      "doi-asserted-by": "crossref",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "493_CR56",
      "unstructured": "Lee SE, Lee HS, Kim K-Y, Park J-H, Roh H, Park HY, et al. High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer. Sci Rep. 2019;9(1):1–10.",
      "volume": "9",
      "year": "2019"
    },
    {
      "DOI": "10.1093/nar/gkl944",
      "author": "G Plotz",
      "doi-asserted-by": "publisher",
      "first-page": "6574",
      "issue": "22",
      "journal-title": "Nucleic Acids Res",
      "key": "493_CR57",
      "unstructured": "Plotz G, Welsch C, Giron-Monzon L, Friedhoff P, Albrecht M, Piiper A, et al. Mutations in the MutSα interaction interface of MLH1 can abolish DNA mismatch repair. Nucleic Acids Res. 2006;34(22):6574–86.",
      "volume": "34",
      "year": "2006"
    },
    {
      "DOI": "10.1200/JCO.2000.18.1.87",
      "author": "H Mackay",
      "doi-asserted-by": "publisher",
      "first-page": "87",
      "issue": "1",
      "journal-title": "J Clin Oncol",
      "key": "493_CR58",
      "unstructured": "Mackay H, Cameron D, Rahilly M, Mackean M, Paul J, Kaye S, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol. 2000;18(1):87.",
      "volume": "18",
      "year": "2000"
    },
    {
      "DOI": "10.3390/cancers11081126",
      "author": "P Bhateja",
      "doi-asserted-by": "publisher",
      "first-page": "1126",
      "issue": "8",
      "journal-title": "Cancers",
      "key": "493_CR59",
      "unstructured": "Bhateja P, Cherian M, Majumder S, Ramaswamy B. The Hedgehog signaling pathway: a viable target in breast cancer? Cancers. 2019;11(8):1126.",
      "volume": "11",
      "year": "2019"
    },
    {
      "DOI": "10.3390/ijms21186863",
      "author": "K-S Jeng",
      "doi-asserted-by": "publisher",
      "first-page": "6863",
      "issue": "18",
      "journal-title": "Int J Mol Sci",
      "key": "493_CR60",
      "unstructured": "Jeng K-S, Sheen I-S, Leu C-M, Tseng P-H, Chang C-F. The role of smoothened in cancer. Int J Mol Sci. 2020;21(18):6863.",
      "volume": "21",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s12094-019-02042-w",
      "author": "X Jin",
      "doi-asserted-by": "publisher",
      "first-page": "1207",
      "journal-title": "Clin Transl Oncol",
      "key": "493_CR61",
      "unstructured": "Jin X, Zhu L, Cui Z, Tang J, Xie M, Ren G. Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis. Clin Transl Oncol. 2019;21:1207–19.",
      "volume": "21",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1913948",
      "author": "L Dorling",
      "doi-asserted-by": "publisher",
      "first-page": "428",
      "issue": "5",
      "journal-title": "N Engl J Med",
      "key": "493_CR62",
      "unstructured": "Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlström C, et al. Breast cancer risk genes-association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428–39.",
      "volume": "384",
      "year": "2021"
    },
    {
      "DOI": "10.1002/(SICI)1097-0215(20000120)89:1\u003c92::AID-IJC15\u003e3.0.CO;2-8",
      "author": "M Takahashi",
      "doi-asserted-by": "publisher",
      "first-page": "92",
      "issue": "1",
      "journal-title": "Int J Cancer",
      "key": "493_CR63",
      "unstructured": "Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, et al. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer. 2000;89(1):92–9.",
      "volume": "89",
      "year": "2000"
    },
    {
      "DOI": "10.1101/mcs.a001362",
      "author": "K Purshouse",
      "doi-asserted-by": "publisher",
      "issue": "3",
      "journal-title": "Mol Case Stud",
      "key": "493_CR64",
      "unstructured": "Purshouse K, Schuh A, Fairfax BP, Knight S, Antoniou P, Dreau H, et al. Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer. Mol Case Stud. 2017;3(3): a001362.",
      "volume": "3",
      "year": "2017"
    }
  ],
  "reference-count": 64,
  "references-count": 64,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00493-5"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "17"
}